Omentin-1 vs Roxadustat
Head-to-head comparison of Omentin-1 (Omentin-1 (Intelectin-1, ITLN1)) and Roxadustat (Roxadustat (FG-4592), hypoxia-inducible factor prolyl hydroxylase inhibitor) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Omentin-1 | Roxadustat |
|---|---|---|
| Category | Diabetes & Metabolic | Muscle & Performance |
| Full Name | Omentin-1 (Intelectin-1, ITLN1) | Roxadustat (FG-4592), hypoxia-inducible factor prolyl hydroxylase inhibitor |
| Molecular Weight | ~35 kDa | 352.35 Da |
| Half-Life | hours | ~12-16 h |
| Amino Acids | 313 | N/A |
| Typical Dose | No approved human dose; research use only | 70-100 mg orally three times weekly |
| Route | IV|SC | Oral |
| Purity | ≥98% | ≥98% |
| Studies Count | 82 | 180 |
| Research Status | Pre-clinical | Clinical |
Omentin-1 Benefits
- ✓insulin sensitivity
- ✓glucose uptake
- ✓lipid handling
Roxadustat Benefits
- ✓induces endogenous EPO
- ✓improves iron handling
- ✓raises hemoglobin
- ✓may improve exercise tolerance
Omentin-1 Dosing
not established|not established
Roxadustat Dosing
70-100 mg orally 3x weekly|Titrate by hemoglobin response|Monitor iron indices regularly
Omentin-1 Side Effects
- ⚠unknown
- ⚠immunogenicity risk
Roxadustat Side Effects
- ⚠nausea
- ⚠hypertension
- ⚠thrombotic events
Research Overview
Omentin-1
Lower omentin-1 levels are often associated with obesity, insulin resistance, and metabolic syndrome. Research continues on its use as a biomarker and as a mechanistic lead for AMPK-linked metabolic interventions.
Roxadustat
Large clinical studies support roxadustat for anemia, especially in chronic kidney disease populations. Direct VO2 max enhancement data in healthy athletes are limited, so its performance effects remain mostly inferential.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.